Posts tagged Section 505(q).
Blogs
3 minute read
On October 2, 2018, FDA Commissioner Scott Gottlieb released a statement announcing new agency actions to further deter “gaming” of the generic drug approval process through the use of citizen petitions. Among these actions, the most significant was the issuance of a revised draft guidance on citizen petitions subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act (“FDCA”), published on the same day. The stated goal of this revision was to create a more efficient approach to 505(q) petitions and to allow the Agency to focus reviewer resources on scientific ...
Blog Editors
Recent Updates
- AI Infrastructure, Ideology, and Exports: Inside the White House’s New AI Orders
- Texas Judge Strikes Down HIPAA’s Reproductive Health Amendment
- White House AI Action Plan Drops: Here’s What We Know
- AI Policy Alert: What to Know Before the White House Releases Its AI Action Plan
- Ninth Circuit Applies EKRA to Marketing Intermediaries in Lab Operator’s Allergy Testing Scheme